awmsg logo



anakinra (Kineret®)


Reference No. 1962

Publication date:
08/05/2014


Appraisal information

anakinra (Kineret®) 100 mg/0.67 ml solution for injection


Company: Swedish Orphan Biovitrum Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 07/05/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, anakinra (Kineret®) cannot be endorsed for use within NHS Wales for the treatment of cryopyrin-associated periodic syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above, including: neonatal-onset multisystem inflammatory disease/chronic infantile neurological, cutaneous, articular syndrome; Muckle-Wells syndrome; and familial cold autoinflammatory syndrome.
Statement of Advice (SOA)
Download